Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 86

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 86
---
's chief operating decision maker (CODM) is the chief executive officer. The Company manages the business activities on a consolidated basis. The CODM assesses performance of the Company, and decides how to allocate resources based on net income, which is reported in the consolidated statement of earnings as net earnings and allocates resources on a consolidated basis. The CODM uses net earnings to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings is also used to monitor budget versus actual results.The measure of the reportable segment assets is reported on the balance sheet as total assets. The accounting policies of the reportable segment are the same as those described in Note 2, Summary of Significant Accounting Policies.

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)13. Segment Reporting (Continued)

The following table shows the segment revenue, significant segment expenses and net earnings (dollars in thousands):Year Ended December 31,202420232022Total revenues$661,817 $607,521 $667,238 Less: Significant Segment Expenses:Cost of goods sold77,906 83,779 87,221 Selling153,105 149,955 147,289 Marketing74,188 79,231 120,499 General and administrative94,289 107,175 109,433 Research and development expensesExternal development program expenses:ONAPGO1,641 3,825 1,942 SPN-82027,042 12,311 8,139 SPN-8179,837 9,397 7,341 Qelbree15,819 11,101 8,641 Early-stage programs and other expenses16,352 20,467 16,929 Total external development program expenses70,691 57,101 42,992 Internal employee-related expenses38,105 34,492 31,560 Total research and development expenses108,796 91,593 74,552 Other segment items(a)79,668 94,472 67,533 Net earnings$73,865 $1,316 $60,711 (a) Other segment items include amortization of intangible assets, intangible asset impairment charges, contingent consideration gain, net interest and other income, interest expense, and income tax expense, whose amounts are disclosed in the